First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
Open Access
- 20 May 2022
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (7) , 1684-1695
Abstract
No abstract availableKeywords
Funding Information
- Bayer
This publication has 26 references indexed in Scilit:
- Generation and characterization of aptamers targeting factor XIaThrombosis Research, 2017
- Factor 11 single-nucleotide variants in women with heavy menstrual bleedingJournal of Obstetrics and Gynaecology, 2017
- Factor XI as a Therapeutic TargetArteriosclerosis, Thrombosis, and Vascular Biology, 2016
- Gynaecological and obstetrical bleeding in women with factor XI deficiency – a systematic reviewHaemophilia, 2015
- Factor XI and contact activation as targets for antithrombotic therapyJournal of Thrombosis and Haemostasis, 2015
- Factor XI Antisense Oligonucleotide for Venous ThrombosisNew England Journal of Medicine, 2015
- Factor XI Antisense Oligonucleotide for Prevention of Venous ThrombosisNew England Journal of Medicine, 2015
- Designing Allosteric Inhibitors of Factor XIa. Lessons from the Interactions of Sulfated PentagalloylglucopyranosidesJournal of Medicinal Chemistry, 2014
- Allosteric Inhibition of Human Factor XIa: Discovery of Monosulfated Benzofurans as a Class of Promising InhibitorsJournal of Medicinal Chemistry, 2014
- Clinical Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010